4.3 Review

Lipidomics and Biomarker Discovery in Kidney Disease

Journal

SEMINARS IN NEPHROLOGY
Volume 38, Issue 2, Pages 127-141

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semnephrol.2018.01.004

Keywords

Lipidomics; biomarkers; mass spectrometry; metabolomics

Funding

  1. National Institutes of Health [K08DK106523, P30DK089503, DK082841, P30DK081943, P30DK020572, DK097153]
  2. Clinical and Translational Science Award (CTSA) by Michigan Institute for Clinical and Health Research (MICHR) [UL1TR000433]

Ask authors/readers for more resources

Technological advances in mass spectrometrybased lipidomic platforms have provided the opportunity for comprehensive profiling of lipids in biological samples and shown alterations in the lipidome that occur in metabolic disorders. A lipidomic approach serves as a powerful tool for biomarker discovery and gaining insight to molecular mechanisms of disease, especially when integrated with other -omics platforms (ie, transcriptomics, proteomics, and metabolomics) in the context of systems biology. In this review, we describe the workflow commonly applied to the conduct of lipidomic studies including important aspects of study design, sample preparation, biomarker identification and quantification, and data processing and analysis, as well as crucial considerations in clinical applications. We also review some recent studies of the application of lipidomic platforms that highlight the potential of lipid biomarkers and add to our understanding of the molecular basis of kidney disease. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available